GNI Group Ltd. (2160) Stock Price

GNI Group operates two main business segments: pharmaceuticals and medical devices. In the pharmaceutical business, the company conducts research, development, and manufacturing of drug compounds, with a focus on "Aisuryui," which is sold in the Chinese market, and "F351," which has completed clinical trials.

The medical device business is primarily based in the United States and focuses on the development and manufacturing of biomaterials. The company also provides services as a designated medical device manufacturer and importer (DMAH) and as an investigational new drug domestic coordinator (ICC). Through these operations, GNI Group delivers diversified medical-related services.

Key affiliated companies of GNI Group include Shanghai Genomics Co., Ltd., Beijing Continent Pharmaceuticals Co., Ltd., and GNI Hong Kong Limited. These companies form the core of the pharmaceutical business and strengthen the group's competitiveness in global markets.

In the medical device business, Berkeley Advanced Biomaterials LLC, Berkeley Biologics LLC, and Micren Healthcare Inc. operate as principal affiliated companies. These entities contribute to the development and advancement of cutting-edge medical technologies.

GNI Group is a global healthcare company with a mission to meet unmet medical needs. The company's core strategy is continuous investment in innovative drug development and expansion of profitability, while adapting to external market changes and returning profits to shareholders.

The company pursues sustainable growth by efficiently managing research and development investments in pharmaceuticals and medical devices, and diversifying revenue sources. In the pharmaceutical business, the company targets 20-40% sales growth through new drug launches and expanded indications. In the medical device business, it aims to secure appropriate profits through new product introductions and expansion into the aesthetics sector.

GNI Group's growth strategy centers on strengthening drug discovery investment and manufacturing/sales operations in the pharmaceutical business, and expanding the medical device business. The company particularly leverages cost advantages from vertical integration in the Chinese market while pursuing business expansion in the United States.

In new drug development strategy, the company focuses on developing breakthrough pharmaceuticals that address urgent medical needs. By utilizing China's research and development capabilities, the company aims to expand indications and enter global markets, thereby providing treatment to more patients.

To ensure sustainable revenue, the company is strengthening manufacturing and sales of Beijing Continent's flagship pharmaceutical "Aisuluyi," expanding indications, and enhancing its sales portfolio. Additionally, the company is advancing medical device operations in the United States and pursuing revenue expansion through applications in the aesthetics field.

GNI Group conducts strategic investments in innovative companies where synergies are expected, leveraging expertise cultivated through its pharmaceutical and medical device businesses. This approach aims to accelerate growth across the entire group.

The company also considers business expansion in the Japanese market, aiming to establish new business pillars through M&A and business partnerships. This will further strengthen global business operations.

The company also prioritizes ESG (environmental, social, and governance) initiatives, promoting social contribution through business activities. In particular, in China, the company actively pursues social contributions and environmental protection efforts.